Abbott Laboratories saw its third-quarter revenue rise 5.8 percent, to $5.1 billion, thanks to strong sales of branded pharmaceuticals and nutrition goods, along with a boost in its vision care products.
Abbott Laboratories (NYSE:ABT) released the earnings results from its third quarter before opening bell this morning, posting adjusted earnings of 62 cents per share, a 12.7% growth rate, on $5.1 billion in revenue.
ABBOTT PARK, Ill., Sept. 26, 2014 - Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets.
Abbott Laboratories (NYSE:ABT) and Mylan Inc (NASDAQ:MYL) announced today that the two companies still plan to go ahead with their $5.3 billion merger despite the announcement of new tax rules on September 22.
Investors in Abbott Laboratories (NYSE: ABT) saw new options begin trading today, for the January 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 830 days until expiration ...